Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT06232122 Recruiting - Ovarian Cancer Clinical Trials

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy

NCT ID: NCT06229366 Recruiting - Prostate Cancer Clinical Trials

[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer

ACCEL
Start date: March 26, 2024
Phase: Phase 1
Study type: Interventional

ACCEL is a multicenter, open label phase I/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

NCT ID: NCT06228599 Recruiting - Pancreas Cancer Clinical Trials

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

PROTECT-PANC
Start date: February 29, 2024
Phase: N/A
Study type: Interventional

This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

NCT ID: NCT06228079 Not yet recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial

NCT ID: NCT06226519 Recruiting - Clinical trials for Pediatric Brain Tumor

Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children

Start date: May 13, 2020
Phase:
Study type: Observational

Nuclear magnetic resonance imaging (NMR) is used in pediatric brain tumors for purposes of diagnosis, evaluation of response to treatments, and monitoring of patients in follow-up. Through conventional imaging techniques it remains difficult to differentiate tumor recurrence from pseudo-progression or other iatrogenic changes after radiotherapy or chemotherapy, but it remains a relevant and essential clinical need for patient management.

NCT ID: NCT06225310 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

KPT-IST-391
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

NCT ID: NCT06224166 Recruiting - Clinical trials for Head and Neck Tumors

Analysis of HPV and Biomarkers Present in the Biological Fluids of Patients Suffering From Head and Neck Cancer as a Non-invasive Strategy for Detecting Recurrence

Start date: January 17, 2023
Phase:
Study type: Observational

Multicenter, non-interventional, retrospective/prospective biological study on patients affected by head and neck tumors, for which the collection and use of tissue samples, blood and saliva for the detection of HPV-DNA/RNA and miRNA.

NCT ID: NCT06223880 Recruiting - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Start date: December 27, 2023
Phase: Phase 4
Study type: Interventional

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

NCT ID: NCT06223074 Enrolling by invitation - Methylprednisolone Clinical Trials

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

IN-DXM-EMRR
Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

NCT ID: NCT06220552 Recruiting - Clinical trials for Recurrent Glioblastoma

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Start date: December 27, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of low-dose radiotherapy combined with programmed death 1 (PD-1) inhibitor (sintilimab) and temozolomide in recurrent glioblastoma. The eligible patients are scheduled to administered sintilimab 200mg D1 Q3W temozolomide 50mg/m2 QD and radiotherapy 1Gy/1F D1/D2/D8/D15 Q3W for 4-6 cycles, then sintilimab for maintenance. The overall primary study hypothesis is that the combination regimen of low-dose radiotherapy, sintilimab and temozolomide is safe and feasible in the treatment of recurrent glioblastoma.